| Literature DB >> 30551501 |
Zahra Payandeh1, Armina Alagheband Bahrami2, Reyhaneh Hoseinpoor2, Yousef Mortazavi3, Masoumeh Rajabibazl4, Azam Rahimpour5, Amir Hossein Taromchi6, Saeed Khalil7.
Abstract
B-lymphocyte antigen CD20 (called CD20) is known as an activated-glycosylated phosphoprotein which is expressed on the surface of all B-cells. CD20 is involved in the regulation of trans-membrane Ca2+ conductance and also play critical roles in cell-cycle progression during human B cell proliferation and activation. The appearance of monoclonal antibody (mAb) technology provided an effective field for targeted therapy in treatment of a variety of diseases such as cancer, and autoimmune diseases. Anti-CD20 is one of important antibodies which could be employed in treatment of several diseases. Increasing evidences revealed that efficacy of different anti-CD20 antibodies is implicated by their function. Hence, evaluation of anti-CD20 antibodies function could provide and introduce new anti-CD20 based therapies. In the present study, we summarized several applications of anti-CD20 antibodies in various immune related disorders including B-CLL (B-cell chronic lymphocytic leukemia), rheumatoid arthritis (RA), multiple sclerosis (MS) and melanoma.Entities:
Keywords: B-cell chronic lymphocytic leukemia; CD20; Melanoma; Monoclonal antibody; Multiple sclerosis; Rheumatoid arthritis
Mesh：
Substances：
Year: 2018 PMID： 30551501 DOI： 10.1016/j.biopha.2018.11.121
Source DB: PubMed Journal: Biomed Pharmacother ISSN： 0753-3322 Impact factor: 6.529